Ardelyx Taps Atara Biotherapeutics CMO Rajani Dinavahi to Lead Medical Strategy
Event summary
- Rajani Dinavahi, MD, appointed Chief Medical Officer of Ardelyx on April 1, 2026.
- Dinavahi brings over 20 years of experience in healthcare and biotechnology, with a focus on immuno-oncology, autoimmune diseases, and metabolic disease.
- Previously served as Senior Vice President and CMO at Atara Biotherapeutics, leading global development and medical affairs.
- Ardelyx has two commercial products, IBSRELA® and XPHOZAH®, and a pipeline including Phase 3 development of tenapanor for chronic idiopathic constipation.
The big picture
Ardelyx's appointment of Rajani Dinavahi as CMO underscores its focus on strengthening medical leadership amid a critical growth phase. Dinavahi's extensive experience in immuno-oncology and autoimmune diseases aligns with Ardelyx's pipeline strategy, particularly in advancing tenapanor for chronic idiopathic constipation. The move reflects a broader industry trend of biopharmaceutical companies prioritizing clinical expertise to drive innovation and regulatory success.
What we're watching
- Pipeline Acceleration
- How Dinavahi's experience in advancing therapies from early development through Phase 3 will impact Ardelyx's pipeline momentum.
- Regulatory Strategy
- Whether Dinavahi's background in global development programs and regulatory filings will streamline Ardelyx's approval processes.
- Commercial Execution
- The pace at which Ardelyx can leverage Dinavahi's leadership to strengthen its commercial capabilities and expand market reach.